Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50+
SponsorBeijing Anlong Biopharmaceutical Co., Ltd.
About this trial
This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD. Eligible patients, are those who were previously enrolled in a clinical study in which they received a single dose of AL-001 administered via suprachoroidal space injection.
Eligibility criteria
Qualifiers
The subjects enrolled in AL-001 study and received AL-001 ophthalmic injection.
The subject or their legal representative agrees to participate in this study and signs a written ICF.
The subjects are willing and able to follow planned visits and procedures.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
21 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov